About Us
Signaling a new era in T2D therapy
Endogenex, in partnership with Mayo Clinic, aims to revolutionize treatment options for individuals with type 2 diabetes (T2D). Endogenex’s innovations focus on resetting the body’s metabolic signaling system by harnessing its natural regenerative capabilities to improve metabolic function.
Through the development of the ReCET™ System and the novel application of precise, controlled, non-thermal pulsed electric fields, Endogenex is establishing a new era in treatment options for people living with T2D, helping patients regain control of their blood glucose levels and slow disease progression.
Endogenex is a privately held, clinical-stage company based in Minneapolis, MN.
Leadership
Stacey Pugh
Lian Cunningham, MD, PhD
Lian brings 20+ years of clinical affairs and leadership experience to the Endogenex team. Her prior leadership roles include VP of clinical affairs at both BAROnova and TriReme Medical, Inc., and medical director/VP of clinical research and education at VNUSMedical Technologies (acquired by Covidien). Earlier in her career, Lian was an assistant professor at Loyola University of Chicago and a practicing vascular surgeon in Shanghai, China.
Brent Collins
Brent has more than 25 years of proven success bringing early-stage medical technologies from concept to global commercialization. He has served in leadership roles at Torax Medical (acquired by Johnson & Johnson), St. Jude Medical, ACIST Medical (acquired by Bracco Group) and Cascade Medical. He has a BS in business administration and marketing from University of St. Thomas.
Chris Sorli, MD, PhD
Dr. Sorli is an expert in the field of metabolic disorders including diabetes management. He has held leadership positions at Acerus Pharmaceutical and Sanofi where he led strategy and execution of all Medical Affairs activities across a broad product portfolio. Dr. Sorli is board certified in Endocrinology, Diabetes and Metabolism, and Internal Medicine and led The Center of Excellence in Diabetes and Metabolism, a clinical research center and metabolic surgery program in Billings, MT. He is a nationally and internationally recognized researcher and presenter on the topics of Type 2 Diabetes, Obesity, Metabolic Disease, and Metabolic Syndrome.
Melanie Hess
Melanie has over 20 years of medical industry experience specializing in regulatory strategy, compliance and global regulatory affairs. Prior to joining Endogenex, she held regulatory positions at Osprey Medical, American Medical Systems, Endo Pharmaceutical (AMS) and St. Jude Medical. Melanie spent 8 years as an intensive/critical care RN. She holds a BSN from the University of Minnesota and an MBA from the University of Phoenix.
Matt Cambronne
Matt brings two decades of design, development, and technical leadership expertise in the medical device industry. Before joining Endogenex he held positions of increasing responsibility at Boston Scientific and Cardiovascular Systems, Inc. (acquired by Abbott, Inc.) where he led new product development for a portfolio of 510(k) and PMA medical devices with a scope spanning research, development, manufacturing, reliability and program management.
Matt received a BSc Degree in Materials Sciences and Engineering from Iowa State University and an MBA from Augsburg College.
Board of Directors
Juliet Tammenoms Bakker
Co-Founder and Managing Director Longitude Capital